DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

28 Drugs in Development

28 Drugs in Development

DIGITAL CONTENT

37 NEWS #PharmaBuzz

media
37 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

28DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1257628-77-5, Gzd824, Olverembatinib, Gzd-824, Hqp1351, Olverembatinib [usan]

Molecular Formula

C₂₉H₂₇F₃N₆O

Molecular Weight

532.6 g/mol

InChI Key

TZKBVRDEOITLRB-UHFFFAOYSA-N

FDA UNII

KV1M7Q3CBP

Olverembatinib is an orally bioavailable inhibitor of a variety of kinases, including the Bcr-Abl tyrosine kinase, the mast/stem cell growth factor receptor Kit (c-Kit), the serine/threonine protein kinase Akt (protein kinase B), and the extracellular signal-regulated kinase (ERK) with antineoplastic activity. Upon administration,olverembatinib targets, binds to and inhibits the kinase activities of Bcr-Abl, AKT, c-Kit and ERK. This inhibits their mediated signaling pathways and inhibits proliferation of tumor cells in which these kinases are overexpressed and/or mutated. Bcr-Abl, c-Kit, AKT and ERK play key roles in the proliferation, differentiation and survival of tumor cells.

1 2D Structure

Olverembatinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide

2.1.2 InChI

InChI=1S/C29H27F3N6O/c1-19-3-5-22(14-21(19)6-4-20-13-24-17-34-36-27(24)33-16-20)28(39)35-25-8-7-23(26(15-25)29(30,31)32)18-38-11-9-37(2)10-12-38/h3,5,7-8,13-17H,9-12,18H2,1-2H3,(H,35,39)(H,33,34,36)

2.1.3 InChI Key

TZKBVRDEOITLRB-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CC5=C(NN=C5)N=C4

2.2 Other Identifiers

2.2.1 UNII

KV1M7Q3CBP

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 3-((1h-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)-4-methyl-n-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide

2. 4-methyl-n-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1h-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)benzamide

3. Benzamide, 4-methyl-n-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1h-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)-, Methanesulfonate (1:2)

4. D-824

5. D-824 Dimesylate

6. D824

7. Gzd-824

8. Gzd-824 Dimesylate

9. Gzd824

10. Hqp-1351

11. Hqp-1351 Dimesylate

12. Hqp1351

13. Hqp1351 Dimesylate

14. Olverembatinib

15. Olverembatinib Dimesylate

2.3.2 Depositor-Supplied Synonyms

1. 1257628-77-5

2. Gzd824

3. Olverembatinib

4. Gzd-824

5. Hqp1351

6. Olverembatinib [usan]

7. Hqp-1351

8. Kv1m7q3cbp

9. 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide

10. Chembl2316582

11. D-824

12. Gzd 824

13. Benzamide, 4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]-

14. Olverembatinib Dimesylate

15. Hqp1351 Dimesylate

16. Hqp-1351 Dimesylate

17. 4-methyl-n-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1h-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)benzamide

18. Benzamide, 4-methyl-n-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1h-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)-

19. 4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide

20. 4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-(2-{1h-pyrazolo[3,4-b]pyridin-5-yl}ethynyl)benzamide

21. Hqp1351 Free Base

22. Hqp-1351 Free Base

23. Unii-kv1m7q3cbp

24. Olverembatinib [inn]

25. Schembl3424528

26. Olverembatinib [who-dd]

27. Gtpl10630

28. Ex-a829

29. Bcp07502

30. Bdbm50425780

31. Who 11221

32. Zinc95594040

33. Akos026750647

34. Cs-1444

35. Sb16617

36. Compound 10a [pmid: 23301703]

37. Ncgc00351607-06

38. Ac-35436

39. As-75170

40. Hy-15666

41. Ft-0700150

42. A16264

43. C72036

44. A899056

45. J-690110

2.4 Create Date

2011-04-25

3 Chemical and Physical Properties

Molecular Formula	C₂₉H₂₇F₃N₆O
Molecular Weight	532.6 g/mol
XLogP3	4.6
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	6
Exact Mass	532.21984399 g/mol
Monoisotopic Mass	532.21984399 g/mol
Topological Polar Surface Area	77.2 Å²
Heavy Atom Count	39
Formal Charge	0
Complexity	910
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1